Goldman Sachs
BHVN

Goldman Sachs’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Goldman Sachs’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,000
Closed -$2.07M – 7233
2021
Q4 		$2.07M Sell
15,000
-10,000
-40% -$1.27M ﹤0.01% 4215
2021
Q3 		$3.47M Buy
+25,000
New +$3.12M ﹤0.01% 3681
2021
Q2 		– Sell
-92,400
Closed -$6.32M – 6855
2021
Q1 		$6.32M Sell
92,400
-145,200
-61% -$11.7M ﹤0.01% 2932
2020
Q4 		$20.4M Buy
237,600
+199,600
+525% +$16.9M 0.01% 1843
2020
Q3 		$2.47M Buy
38,000
+8,000
+27% +$524K ﹤0.01% 3425
2020
Q2 		$2.19M Buy
+30,000
New +$1.6M ﹤0.01% 3387
2020
Q1 		– Sell
-37,100
Closed -$2.02M – 5781
2019
Q4 		$2.02M Sell
37,100
-265,400
-88% -$13.1M ﹤0.01% 3638
2019
Q3 		$12.6M Sell
302,500
-11,900
-4% -$503K ﹤0.01% 2155
2019
Q2 		$13.8M Buy
+314,400
New +$17.7M ﹤0.01% 2133

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Goldman Sachs's BHVN Position: Q4 2022 in Review

Goldman Sachs sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 1,062,350 shares — an estimated $161M sold.

Goldman Sachs first reported a position in BHVN in Q4 2017 and held it in 20 quarters. The position peaked at $161M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Goldman Sachs reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 1,062,350 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $161M.
  • Goldman Sachs first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 20 quarters.
  • Goldman Sachs's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $161M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.